Compare HWKN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | MLYS |
|---|---|---|
| Founded | 1938 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | N/A | 2023 |
| Metric | HWKN | MLYS |
|---|---|---|
| Price | $134.95 | $39.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $200.00 | $46.40 |
| AVG Volume (30 Days) | 147.6K | ★ 1.8M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ 1.59 | N/A |
| EPS | ★ 3.97 | N/A |
| Revenue | ★ $1,045,229,000.00 | N/A |
| Revenue This Year | $15.55 | N/A |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | $34.13 | ★ N/A |
| Revenue Growth | ★ 11.86 | N/A |
| 52 Week Low | $98.30 | $8.24 |
| 52 Week High | $186.15 | $47.65 |
| Indicator | HWKN | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 44.02 |
| Support Level | $127.65 | $41.50 |
| Resistance Level | $132.48 | $44.13 |
| Average True Range (ATR) | 5.50 | 3.07 |
| MACD | 2.35 | -0.49 |
| Stochastic Oscillator | 93.13 | 40.44 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.